Your browser doesn't support javascript.
loading
Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil.
Bokel, Joanna; Martins-Gonçalves, Remy; Grinsztejn, Eduarda; Mendes-de-Almeida, Daniela P; Hoagland, Brenda; Cardoso, Sandra Wagner; Geraldo, Kim Mattos; Coutinho, Sandro Nazer; Georg, Ingebourg; Oliveira, Maria Helena; Dos Santos Souza, Flávia; Sacramento, Carolina Q; Rozini, Stephane V; Vizzoni, Alexandre G; Veloso, Valdiléa; Bozza, Patrícia T; Grinsztejn, Beatriz.
Affiliation
  • Bokel J; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil. Electronic address: bokeljoanna@gmail.com.
  • Martins-Gonçalves R; Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Grinsztejn E; University Hospitals, Case Western University, Cleveland, OH, USA.
  • Mendes-de-Almeida DP; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Hoagland B; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Cardoso SW; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Geraldo KM; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Coutinho SN; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Georg I; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Oliveira MH; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Dos Santos Souza F; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Sacramento CQ; Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Rozini SV; Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Vizzoni AG; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Veloso V; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Bozza PT; Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
  • Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
Vaccine ; 42(25): 126175, 2024 Nov 14.
Article in En | MEDLINE | ID: mdl-39107160
ABSTRACT

INTRODUCTION:

The Ad26.COV2·S (Janssen/Johnson & Johnson) COVID-19 vaccine, has been rarely associated with vaccine-induced immune thrombocytopenia and thrombosis (VITT). We investigated the prevalence of anti-PF4 antibody positivity, thrombocytopenia, D-dimer elevation, plasmatic thromboinflammatory markers, and platelet functional assays following Ad26.COV2·S vaccination in Rio de Janeiro, Brazil.

METHODS:

From July to September 2021, participants were assessed prior, 1, and 3 weeks post-vaccination. Platelet count and D-dimer were measured at each visit and anti-PF4 at week 3. A positive anti-PF4 prompted retrospective testing of the sample from week 0. Individuals with new thrombocytopenia or elevated D-dimer, positive anti-PF4, and 38 matched controls without laboratory abnormalities were evaluated for plasmatic p-selectin, tissue factor, and functional platelet activation assays.

RESULTS:

630 individuals were included; 306 (48.57%) females, median age 28 years. Forty-two (6.67%) presented ≥1 laboratory abnormality in week 1 or 3. Five (0.79%) had thrombocytopenia, 31 (4.91%) elevated D-dimer, and 9 (1.57%) had positive anti-PF4 at week 3. Individuals with laboratory abnormalities and controls showed a slight increase in plasmatic p-selectin and tissue factor. Ten individuals with laboratory abnormalities yielded increased surface expression of p-selectin, and their ability to activate platelets in a FcγRIIa dependent manner was further evaluated. Two were partially inhibited by high concentrations of heparin and blockage of FcγRII with IV.3 antibody. Plasma obtained before vaccination produced similar results, suggesting a lack of association with vaccination.

CONCLUSIONS:

Vaccination with Ad26.COV2·S vaccine led to a very low frequency of low-titer positive anti-PF4 antibodies, elevation of D-dimer, and mild thrombocytopenia, with no associated clinically relevant increase in thromboinflammatory markers and platelet activation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrin Fibrinogen Degradation Products / Platelet Factor 4 / Platelet Activation / COVID-19 Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do sul / Brasil Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrin Fibrinogen Degradation Products / Platelet Factor 4 / Platelet Activation / COVID-19 Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do sul / Brasil Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication: